Comparing VMS Therapy Effects on Menopausal Sleep

In this episode, ‘Comparing VMS Therapies and Their Effects on Sleep,’ the panel weighs what the newer nonhormonal therapies and hormone therapy deliver for sleep. Both hormonal and nonhormonal therapies can benefit sleep, but the strength of the evidence differs considerably. Dr. Pinkerton reviews the neurokinin receptor antagonists, which have demonstrated improvements in sleep in addition to vasomotor symptoms (VMS). She explains that the two agents appear to reach sleep through different mechanisms, with elinzanetant's dual activity suggesting a sleep effect that is partly independent of hot flash reduction. She also discusses evidence that hormone therapy can improve sleep, including the calming effect associated with progesterone. The panel considers how these differences should shape the way clinicians discuss expected benefits with patients.

Dr. Bertisch encourages clinicians to look closely at both the size of each effect and the quality of the data behind it. She notes that the pivotal neurokinin trials used validated sleep instruments, an advantage over many older hormone therapy studies. Using that lens, she describes the magnitude of sleep improvement as differing meaningfully between the two agents. She also points out that the certainty of evidence for hormone therapy's sleep benefits has been rated as low.

The discussion broadens to options beyond VMS-directed therapy, including cognitive behavioral therapy for insomnia (CBT-I) and sleep medications that have been studied in women with VMS-associated insomnia. The panel highlights the absence of comparative effectiveness data as a major gap. The episode equips clinicians to look past broad assumptions about which therapies help sleep and to weigh the strength of the supporting evidence. That perspective becomes especially useful when sleep, rather than hot flashes, is the patient's primary concern.

The next episode, "Individualizing Treatment for Menopausal Sleep Disturbances," features Dr. Bertisch on how comorbidities, symptom timing, and patient priorities shape treatment selection.